A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

NCT05374226 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors or Lymphomas

Interventions

BIOLOGICAL: JS019

Sponsor

Suzhou Kebo Ruijun Biotechnology Co., Ltd